---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-067444"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2025-07-11T23:59:59+00:00"
generated_at: "2026-05-18T06:59:35.144227+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma appoints Philip Lemons and Richard Baek to Board of Directors

## Summary
- Board expanded from 5 to 6 members with appointment of Lemons and Baek effective July 10, 2025.
- Philip Lemons, 54, brings clinical R&D expertise; serves as Chief Business Officer at ICE Global Consulting.
- Richard Baek, 33, brings financial oversight and regulatory compliance; VP Finance at Studio City PXL.
- No arrangements or transactions with the company requiring disclosure under Item 404(a).

## SEC filing metadata
- accession: 0001104659-25-067444
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2025-07-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465925067444/0001104659-25-067444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465925067444/tm2520692d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-067444
- JSON: https://secwatch.observer/filing/0001104659-25-067444.json
- Plain text: https://secwatch.observer/filing/0001104659-25-067444.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.